As we delve into the world of big pharmaceutical companies, it’s impossible to ignore the heavy hitters – Eli Lilly, AbbVie, and Pfizer. Their third-quarter results for the year have been made public, holding significant implications for the companies and, by extension, their shareholders.
Eli Lilly and Company, prominently known for manufacturing drugs like Cialis and Prozac, has made substantial advancements in the past quarter. The Indianapolis-based corporation reported revenue of $6.04 billion for Q3, up 9% compared to the same period last year. There was positive growth across most of their portfolio, with key drivers being Trulicity, Verzenio, Jardiance, Taltz, among others. Notable was the contribution of the company’s COVID-19 Neutralizing Antibody, which contributed $455 million. This revenue growth and product demand reflect a stable investment base, painting a promising picture for shareholders.
AbbVie, on the other hand, creates and sells advanced therapies and services, which include well-known drugs like Humira, Imbruvica, and Skyrizi. In its Q3 report, AbbVie marked net revenues of $14.82 billion, an increase of 4.8% on a reported basis. Even though the sales of Humira in the U.S declined slightly, the international sales of the product surged by nearly 9.2%. Additionally, AbbVie’s hematologic oncology portfolio contributed significantly to the sales with an increase of 11.5%. The positive Q3 results seem to illustrate a secure platform for the investors.
Pfizer Inc., a global pharmaceutical giant and Covid-19 vaccine pioneer, had an impressive quarter with surprising results. The company reported revenues of $24.1 billion, a considerable 134% operational growth compared to the same period last year. Much of this success can be attributed to the sales of their mRNA Covid-19 vaccine which has generated about $13.1 billion. Besides, Pfizer’s Oncology, Internal Medicine, and Hospital businesses also made notable contributions. These numbers undeniably represent an attractive prospect for investors today.
Each of these big pharma stocks have displayed promising results during this third quarter. Key product performances and unexpected developments, such as the revenue from COVID-19 vaccines, have demonstrated their resilience and growth capacity in a globally challenging time.
Given the tumultuous nature of the global economy amidst a pandemic, these pharmaceutical giants have managed not just to stay afloat but to thrive. Eli Lilly, AbbVie, and Pfizer have shown significant increase in revenues and consistent growth in crucial segments. Together, they continue to play a crucial role in shaping the future of global healthcare, providing better prospects for investors, and helping in the broader fight against the pandemic.
